TriangleDaratumumab / Hyaluronidase Injection (NCT05289687)
Daratumumab / Hyaluronidase Injection trial for T-cell Acute Lymphoblastic Leukemia (NCT05289687). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with T-cell acute lymphoblastic leukemia in morphologic remission, but persistent or recurrent measurable residual disease after at least two intensive chemotherapy blocks. Central testing must confirm residual disease of at least 0.01%.
The idea: daratumumab-hyaluronidase injections target CD38 to help kill leukemia cells. Four weekly doses precede marrow testing. Treatment depends on residual disease; patients who remain positive receive added chemotherapy. Researchers assess residual-disease clearance, relapse and safety.
This phase 2 study plans 20 patients. Shira Dinner leads it at Northwestern in Chicago, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.